MedTrace Logo

Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

NCT01601093 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 288

Last updated 2019-07-05

No results posted yet for this study

Summary

In the proposed study, the investigators plan to evaluate the efficacy and safety of Ceftazidime Sodium and Sulbactam Sodium for Injection(2:1) for the treatment of respiratory and urinary tract acute bacterial infection.

Conditions

Interventions

DRUG

High dose

Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.

DRUG

Low dose

Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.

DRUG

Cefoperazone and Sulbactam Sodium (CFP/SUB)

Cefoperazone 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.

Sponsors & Collaborators

  • Xiangbei Welman Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • hong wh wang, doctor · The first affliated hospital with Nanjing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2022-08-15
Completion
2022-12-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01601093 on ClinicalTrials.gov